Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
Go back to Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA| INTELSAT S. A. (NYSE: I) | Delayed: 0.38 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.38 | 52 Week High | $6.45 | |||
| Open | $0.15 | 52 Week Low | $1.44 | |||
| Day High | $0.38 | P/E | N/A | |||
| Day Low | $0.38 | EPS | $-2.60 | |||
| Volume | 2,550 | |||||
| INTELLIPHARMACEUT (NASDAQ: IPCI) | Delayed: 0.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.21 | 52 Week High | $3.33 | |||
| Open | $268.79 | 52 Week Low | $1.41 | |||
| Day High | $0.21 | P/E | N/A | |||
| Day Low | $0.21 | EPS | $0.00 | |||
| Volume | 0 | |||||
